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Abstract
Background: The Health-Related Quality of Life (HRQoL) assessment in atrial fibrillation (AF)
patients has traditionally been carried out in a poorly standardised fashion, or via the use of non
disease-specific HRQoL questionnaires. The development of a HRQoL questionnaire with a good
measuring performance will allow for a standardised assessment of the impact of this disease on
the patient's daily living.
Methods: A bibliography review was conducted to identify the most relevant domains of daily
living in AF patients. Subsequently, a focus group was created with the aid of cardiologists, and 17
patients were interviewed to identify the most-affected HRQoL domains. A qualitative analysis of
the interview answers was performed, which was used to develop a pilot questionnaire
administered to a 112-patient sample. Based on patient responses, an analysis was carried out
following the statistical procedures defined by the Classical Test Theory (CTT) and the Item
Response Theory (IRT). Reliablility was assessed via Cronbach's coefficient alpha and item-total
score correlations. A factorial analysis was performed to determine the number of domains. For
each domain, a Rasch analysis was carried out, in order to reduce and stand hierarchically the
questionnaire items.
Results: By way of the bibliography review and the expert focus group, 10 domains were identified.
The patient interviews allowed for the identification of 286 items that later were downsized to 40
items. The resultant preliminary questionnaire was administered to a 112-patient sample (pilot
study). The Rasch analysis led to the definition of two domains, comprising 7 and 11 items
respectively, which corresponded to the psychological and physical domains (18 items total),
thereby giving rise to the initial AF-QoL-18 questionnaire. Cronbach's coefficient alpha was
acceptable (0.91).
Conclusion: An initial HRQoL questionnaire, AFQoL-18, has been developed to assess HRQoL
in AF patients.
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Background
The main objective of the management of atrial fibrilla-
tion (AF) patients has been to restore and maintain sinus
rhythm, given that palpitations in these patients increase
the risk of stroke and the likelihood of left ventricular dys-
function [1]. The goal of antiarrhythmic therapies is to
relieve symptoms, prevent complications and reduce dis-
ease-related mortality in this population [2]. Other phar-
macological therapy options are aimed at maintaining the
heart rate under control. Non-pharmacological therapy
options include catheter ablation, pacemakers, internal
defibrillation and antiarrhythmic surgery, although the
impact of such therapies on morbidity and mortality is
unknown.
Traditionally, the reduction of morbidity and mortality
rates in these patients has been assessed as the main goal
of the effectiveness of AF therapy [3,4]. Nevertheless, few
studies take into account the impact of the disease and its
treatments on patients' health-related quality of life
(HRQoL), despite HRQoL assessment's being important
for several reasons. In the first place, drug efficacy is
becoming increasingly similar among different agents,
and often a given therapy is selected based on the poten-
tial improvement in the HRQoL, especially in elderly
patients. Secondly, patients' active involvement with phy-
sicians in therapeutic decision making often focuses on
recognizing and choosing the therapeutic option that will
have a lesser impact on the patient's daily living. Lastly,
regulatory authorities increasingly request data on
HRQoL in reports submitted for the approval of new
drugs or therapeutic modalities [3].
Some studies have found that the impact is greater on the
physical domain, and that HRQoL also depends on indi-
vidual experiences, beliefs and expectations regarding the
disease. Sociodemographic variables, like age and gender,
also affect HRQoL, with female patients and those under
the age of 69 obtaining the worst score. [5-7].
HRQoL assessment as part of the clinical management of
AF will allow the practitioner to identify those aspects
often overlooked in clinical practice regarding the
patient's perception of the disease and its course, which in
turn could help improve control over the disease. It has
been observed that restoration of sinus rhythm is the best
predictor of the disease's impact on the patient's HRQoL
[7]. Studies have shown that the correlation between clin-
ical measurements, like time to first AF recurrence, con-
current stroke or symptoms, and subjective measurements
like HRQoL, is poor. The use of specific measurements for
HRQoL will allow a better assessment of the impact of this
disease on patient's daily living while, in addition, other
specific aspects of the disease can be identified. These
would significantly improve the patient's HRQoL through
strategies aimed at minimizing the impact of AF on
HRQoL.
The goal of the present study is to develop a HRQoL-spe-
cific questionnaire for AF patients that can be applied to
any of the types of AF (paroxysmal or permanent). The
project is divided into two phases. The first one focuses on
the development of the preliminary specific question-
naire. The second will focus on the development of the
final questionnaire, following a prospective trial, and on
the assessment of the questionnaire's measurement prop-
erties in a large sample of patients.
In this article, the methodology of the first phase of the
questionnaire's development is explained.
Methods
The HRQoL questionnaire in AF patients (AF-QoL-18)
was developed in three phases: item generation, item
selection and reduction of the items.
Item generation
Firstly, a bibliography review was conducted to identify
the most relevant aspects describing the impact of AF on
the patients' HRQoL. That information was used to elab-
orate a survey for identifying AF-related symptoms as
assessed by three cardiologists specialised in arrhythmias.
With a list of HRQoL domains related to AF, the experts
included each symptom in one of these domains, based
on their own clinical practice. Each symptom was assessed
in terms of its importance for the patient according to the
experts, and the frequency with which it is observed in the
physician's office. Finally, these experts took part in a
Focus Group [8] where previously identified aspects were
discussed and evaluated as necessary in cases of doubt or
discrepancies.
This information was used to create a semi-structured
interview script to be administered to AF patients, in order
to identify which items and domains had the greatest
impact on daily living from the patients' point of view. A
psychologist specialised in the development of patient-
focused scales interviewed a total of 17 AF patients in
three Spanish hospitals in Bilbao and Madrid. All
respondents agreed to have their interviews recorded on
audio. The interviews lasted between 35 and 50 minutes.
After transcribing the interviews, relevant phrases/expres-
sions were obtained for each of the assessed domains [9].
Item selection
An initial qualitative reduction of the identified expres-
sions was carried out, in which expressions considered
inappropriate, ambiguous or redundant were excluded.
The expressions included were slightly reworded as state-Health and Quality of Life Outcomes 2007, 5:37 http://www.hqlo.com/content/5/1/37
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ments capable of being used as items in an initial ques-
tionnaire.
Each expression was assessed at a second experts' meeting,
in terms of clarity (how easy they were to understand from
the patients' perspective), importance (specific relevance of
the expression for AF patients) and frequency (number of
cases in which AF patients utilised the expression), by
means of a Likert-type scale ranging from 1 (not very
clear/frequent/important) to 5 (very clear/frequent/
important) [10]. The information was analysed by assess-
ing the degree of concordance among experts for each
response scale (clarity, importance and frequency) by
means of Cronbach's alpha. A description of the scores
obtained on each scale was made by means of basic
descriptive statistics (mean, median, standard deviation,
minimum value and percentiles for 10 cut-off values, plus
25th and 75th quartiles). Finally, a qualitative reduction
of the items ensued, based on the mean scores derived
from the experts' responses. Other qualitative aspects were
taken into consideration in the item reduction based on
the judgment of HRQoL experts. High clarity was defined
as a mean score greater than 4.33 (percentile 50); high
importance, as a score greater than 4.00 (percentile 75);
high frequency, as a mean score greater than 3.00 (50th
percentile); high frequency X importance, as a mean score
greater than 16.00.
The identified items were edited to create a self-adminis-
tered preliminary questionnaire for a sample of 112
patients with an AF diagnosis in three Spanish hospitals.
Patients received instructions in order to fill in the items
properly, as well as the response scales ('totally agree', 'suf-
ficiently agree', 'neither agree nor disagree', 'sufficiently
disagree', 'totally disagree'). Data regarding age, sex, date
of AF diagnosis and AF type (permanent or paroxysmal)
were gathered for each participant in the pilot study.
Reduction of the items
Based on the patients' responses to the preliminary ques-
tionnaire items, an item analysis was performed following
a strategy based on the Classic Test Theory (CTT) [1] and
the Item Response Theory (IRT) [12], and specifically on
the Rasch analysis [13].
By means of CTT statistics analysis, criteria such as item
internal consistency (analysis of item-total score correla-
tions) and reliability (Cronbach's alpha) were considered.
The combination of items comprising the questionnaire
domains was established by means of exploratory factor
analysis techniques. A Rasch analysis was performed for
each factor selected in order to reduce the questionnaire.
The Rasch model specifies that an individual's response to
each item represents the result of an interaction between
the item's position (calibration) and the person (scores).
This model constructs a line of measurement, with the
items placed hierarchically, and provides a statistical
adjustment indicating to what degree an item describes
the group of subjects responding to the questionnaire
[14,15]. Rasch analyses were carried out using BIGSTEPS
software, version 2.7.3 [14]. The term 'Measure' is a meas-
ure of weight or difficulty for each item (items with a neg-
ative measure indicate more difficult). Georg Rasch
suggests chi-square fit statistics to control the applicability
of data to his model (Rasch 1980). The chi-squares in
common use are known as OUTFIT and INFIT. These are
reported as mean-squares, chi-square statistics divided by
their degrees of freedom, so that they have a ratio-scale
form with expectation 1 and range 0 to +infinity. INFIT
and OUTFIT MNSQ indices > 1.3 were excluded [16]. For
each domain analysed, those items with a separation
below 1 were eliminated. Successive Rasch analyses were
performed until all items in all domains showed an
appropriate capability to fit.
After the Rasch analysis, the items that finally made up the
reduced version of the questionnaire were numbered.
Results
Item generation
Literature on AF and quality of life was reviewed, as well
as HRQoL questionnaires administered to AF patients. A
search in the MEDLINE database for the previous eight
years was conducted to identify topics related to HRQoL
and AF. With the consensus of AF experts, the domains
identified as having the greatest impact on HRQoL were
the physical, psychological, social, daily activities, symp-
toms, cognitive, perception of health, sexuality, energy/
vitality and sleep domains. Although it is not identified in
the literature, the "sleep" domain was included, distin-
guishing between difficulty in falling asleep and sudden
awakening due to the onset of tachycardia or palpitations.
Item selection
Based on the interviews conducted on 17 AF patients, 286
expressions were identified. The number of expressions
was reduced to 94, which constituted the item identifica-
tion questionnaire administered to the experts' group at
their second meeting. The analysis of each item's score
performed by the three experts showed good observer/
expert consistency as regards expression 'importance' and
'frequency' (Cronbach's α 0.73 and 0.80, respectively).
After the elimination of items not fulfilling the criteria
specified in the "Item selection" section in the "Material
and Methods" chapter, a further analysis reduced the total
number of items to 40.
Reduction of the items
The preliminary 40-item questionnaire (henceforth AF-
QoL 40) was self-administered to a pilot sample of 112Health and Quality of Life Outcomes 2007, 5:37 http://www.hqlo.com/content/5/1/37
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patients with an AF diagnosis from 3 Spanish hospitals
(Table 1). Mean age (SD) was 60.52 years (13.43) with a
predominance of male patients (64.3%). 52.7% of the
sample presented paroxysmal AF, and the mean time in
years (SD) from diagnosis was 3.9 years (3.83) (Table 2).
AF-QoL 40 feasibility was completely fulfilled by the
85.7% of the sample. It was noted that the highest per-
centage of unanswered questions was found for items 4,
34, 35, 36 and 37, four of which refer to sexual activity.
As for the internal consistency of the instrument, the
Cronbach's alpha for the 40 items was 0.956.
The global score for the preliminary questionnaire AF-
QoL-40 ranged from 40 (worse HRQoL) to 200 (best
HRQoL). To make data interpretation easier, scores were
standardised from 0 (worst HRQoL) to 100 (best HRQoL)
following this formula:
P 100 = [100/(p max-pmin)]*(preal - pmin)
With the standardised scores, the mean (SD) was 39.4
(20.5) points.
Correlations between each item and the global score
ranged from 0.4 (item 2) to 0.76 (item 14). No item was
excluded based on correlations below 0.4.
A factorial analysis of the 40 items was conducted, and
two factors were clearly identified that, in conjunction,
accounted for 50.2% of the variance explained, the first
Table 1: Preliminary items in the unreduced AF-QoL questionnaire (AF-QoL-40).
Due to my arrhythmia (atrial fibrillation)...
1. I get tired when I climb slopes or stairs.
2. I get more tired than usual when I carry out physical exercise (jogging, playing tennis, swimming, etc.).
3. I have reduced the amount of physical exercise (jogging, playing tennis, swimming, etc.) I perform.
4. I have stopped performing physical exercise (jogging, playing tennis, swimming, etc.).
5. I get tired when I walk for thirty minutes, and I have to rest.
6. I get tired during a brisk walk.
7. I feel palpitations when I run.
8. I get nervous.
9. I have felt depressed since I was diagnosed with the disease.
10. I feel insecure.
11. I am very aware of my heart and my general health.
12. I feel sadder and more depressed than before I was diagnosed with my disease.
13. I get scared when I feel that my heart beats at high speed.
14. I am afraid that something might happen to me while I am alone.
15. I have negative thoughts about my future.
16. I feel depressed when I find that I get tired.
17. I am afraid of having a sudden and unexpected tachycardia.
18. I feel anxious when I have tachycardia.
19. I am afraid that tachycardia will appear again.
20. I feel insecure when I have to travel.
21. I only go to places with hospitals nearby.
22. My disease has an impact on my family life.
23. I find it difficult to get out of the house to carry out any activity.
24. I feel very tired.
25. I feel as if something were pressing against my heart.
26. I feel exhausted and tired during the arrhythmia (tachycardia).
27. I feel a general tiredness after the arrhythmia (tachycardia).
28. I feel depressed when I think that my disease will last forever.
29. I am afraid of pain or of suffering a heart attack.
30. What affects me the most is the helplessness I feel when I suffer a crisis (tachycardia or arrhythmia episode).
31. I feel affected by the impossibility of carrying out certain activities; "I want to, but my body cannot".
32. I am afraid that my disease complicates things.
33. My disease has impaired my quality of life.
34. Changes have occurred in my sexual activity due to the medications I take.
35. Sexual relationships are less frequent than before I was diagnosed with the disease.
36. I get tired during sexual intercourse, and that is a limitation I feel.
37. I am afraid that my heart is "triggered" during sexual intercourse.
38. I feel a lack of vitality/energy to propose activities.
39. I felt more vitality before I was diagnosed with the disease.
40. I wake up at night due to the tachycardia (arrhythmia).Health and Quality of Life Outcomes 2007, 5:37 http://www.hqlo.com/content/5/1/37
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factor had a variance explained of 37.8%, and of 12.3%
the second factor, there was a third factor with only 5.7%
of variance explained. The first factor consists of 21 items
and the second, of 19 items. Item allocation to either of
the two factors is done when the item burden is above 0.4
in any of the two factors. No item was excluded for not
fulfilling this criterion.
Subsequently, a Rasch analysis was performed for each of
the two factors in order to reduce the number of question-
naire items. For the first factor, the number of items was
reduced from 21 to 7 items (henceforth AF-QoL-7) and
the range of locations for this items was -0.70 to 0.59 and
for the second, from 19 to 11 items (henceforth AF-QoL-
11) and the range of locations was greater, -0.87 to 0.72
(Table 3). For both factors, reliability was 0.82 and sepa-
ration was above 2 points.
Based on the content of the items included in each factor,
it can be said that the AF-QoL-7 items deal with the psy-
chological domain while those of the AF-QoL-11 deal
with physical activity. The questionnaire comprising the
AF-QoL-7 and the AF-QoL-11 domains is identified as AF-
QoL-18.
Internal consistency (Cronbach's α) for AF-QoL-18 and
each of the domains was appropriate, with values of 0.91
for the global questionnaire and 0.89 and 0.90 for AF-
QoL-7 and AF-QoL-11, respectively.
The mean score (SD) for both AF-QoL-18 and each of its
domains was similar (ranging from 39.6 to 38.03), and
slightly lower (worse HRQoL) for the physical domain
(AF-QoL-11).
Finally, the reduced version of the questionnaire (AF-
QoL-18) and the 40-item unreduced version (AF-QoL-40)
were compared; correlations were above 0.80 both for the
original instrument as well as for each of the reduced
domains. On the one hand, each factor showed a high
correlation with the AF-QoL-18 questionnaire global
score, while correlation between both factors/domains
was lower (0.51) (Table 4). Table 5 shows a summary of
the most relevant outcomes obtained for the initial 40-
Table 3: Summary of the RASCH analysis for each factor
Rasch analysis for factor # 1 Psychological Domain (AF-QoL-7)
AF-QoL-40 Item Numer Item Measure Error Infit Outfit
30 What affects me the most is the helplessness I feel during a crisis 0.59 0.13 1.09 1.07
32 I am afraid that my disease complicates things. 0.34 0.12 1.09 1.05
29 I am afraid of pain or of suffering a heart attack. 0.13 0.12 0.98 0.92
17 I am afraid of having a sudden and unexpected tachycardia. -0.02 0.12 0.96 0.99
16 I feel depressed when I find that I get tired. -0.05 0.12 1.08 1.09
28 I feel depressed when I think that my disease will last forever. -0.29 0.11 0.79 0.76
15 I have negative thoughts about my future. -0.70 0.11 1.12 1.03
Rasch analysis for factor # 2 Physical Domain (AF-QoL-11)
2 I get more tired than usual when I perform physical exercise 0.72 0.12 1.24 1.17
6 I get tired during a brisk walk. 0.62 0.11 0.94 0.76
39 I felt more vitality before I was diagnosed with the disease. 0.48 0.11 0.98 0.97
4 I have stopped performing physical exercise 0.15 0.10 1.17 1.08
33 My disease has impaired my quality of life. 0.14 0.10 0.97 0.89
31 I feel affected by the impossibility of carrying out certain activities; "I want to, 
but my body cannot".
0.01 0.10 0.81 0.73
35 Sexual relationships are less frequent than before I was diagnosed with the 
disease.
-0.13 0.10 0.96 0.89
5 I get tired when I walk for thirty minutes and I have to rest. -0.16 0.09 1.24 1.06
34 Changes have occurred in my sexual activity due to the medications I take. -0.40 0.09 0.97 1.09
37 I am afraid that my heart is "triggered" during sexual intercourse. -0.56 0.09 1.07 1.10
23 I find it difficult to get out of the house to carry out any activity. -0.87 0.09 1.01 1.05
Table 2: Sociodemographic and clinical characteristics of the 112-
patient sample with AF from three Spanish hospitals
VARIABLE N (%)
Sex
Male 72 (64.3)
Female 40 (35.7)
Age: mean (SD) (years) 60.52 (13.43)
Type of AF N (%)
Permanent AF 53 (47.3)
Paroxysmal AF 59 (52.7)
Time from diagnosis: mean (SD) (years) 3.91 (2.07)Health and Quality of Life Outcomes 2007, 5:37 http://www.hqlo.com/content/5/1/37
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item version and the reduced 18-item one with its
domains/factors.
The analysis of the AF-QoL-18 questionnaire scores and
its domains in terms of age and sex did not show statisti-
cally significant correlations, although it was observed
that women's scores were slightly lower than men's
(worse HRQoL) in the physical domain (AF-QoL-11), and
slightly higher (better HRQoL) in the psychological
domain and the global score (AF-QoL-7 and AF-QoL-18).
Likewise, in terms of time (in years) from AF diagnosis, no
significant correlations were observed for the question-
naire or with either of the two domains. However, statisti-
cally significant differences were observed (p < 0.01) in
the psychological domain (AF-QoL-7) between patients
with paroxysmal AF and permanent AF; impact on
HRQoL was higher in patients with paroxysmal AF. No
statistically significant differences were found for the glo-
bal questionnaire scores (AF-QoL-18) or the physical
domain (AF-QoL-11).
The results obtained in terms of number of items, proper-
ties of cross-section measurement and relationship with
sociodemographic and clinical variables will be further
assessed in the prospective validation study (second phase
of the project).
Discussion
The present article deals with the development of a spe-
cific questionnaire designed to assess HRQoL in AF
patients. The main advantage of a specific questionnaire
with respect to a generic instrument is that the former
allows one to assess domains relevant to and exclusive of
AF, and sensitivity to changes in health status is greater.
In the questionnaire development phase, methodology
based both on CTT and IRT was used, thus yielding com-
plementary results that reinforce the robustness of the
data. Other authors have combined both methodologies
as well in the development of questionnaires, with
equally positive results [17,18].
A limitation in published studies is the poorly standard-
ized methodology for assessing HRQoL in AF patients or
the administration of generic HRQoL questionnaires. The
idea of developing a specific questionnaire based on sys-
tematic methodology arose from the absence of HRQoL
questionnaires exclusive for AF in the literature [19].
Little is known about the impact of AF on daily living in
less severe or asymptomatic cases, since most studies have
assessed HRQoL on symptomatic patients who are intol-
erant or refractory to antiarrhythmic therapy or in those
treated with ablation. This is due to the fact that often-
times HRQoL was assessed in the context of clinical trials.
Other general limitations of the studies assessing HRQoL
Table 5: Summary of the measurement properties
AF-Qol401 AF-Qol182 AF-Qol73 AF-Qol114
N° items 40 18 7 11
Score distribution
Observations 96 97 106 97
Mean 39.41 38.87 39.59 38.03
SD 20.48 21.53 26.58 23.69
Percentile 50 36.56 37.50 33.93 36.36
% score 0 1 (0.9%) 3 (2.7%) 4 (3.6%) 4 (3.6)
% score 100 0 0 2 (1.8%) 0
Item total correlation 0.40–0.76 0.45–0.76 0.74–0.85 0.56–0.76
Reliability 0.956 0.915 0.901 0.891
Rasch analysis
Person separation 3.89 2.55 2.12 2.17
Person reliability 0.94 0.87 0.82 0.82
1 Preliminary and unreduced questionnaire
2 Reduced questionnaire after the Rasch analysis
3 Psychological domain items
4 Physical domain items
Table 4: Correlation between AF-Qol-18, AF-QoL-7 
(psychological) and AF-QoL-11(physical)
AF-Qol 18 AF-Qol7 
(psychological)
AF-Qol11 
(physical)
AF-Qol7 
(psychological)
r = 0.813
p = 0.000
n = 97
AF-Qol11 (physical) r = 0.904
p = 0.000
n = 97
r = 0.514
p = 0.000
n = 97
AF-Qol40 (initial) r = 0.944
p = 0.000
n = 96
r = 0.848
p = 0.000
n = 96
r = 0.802
p = 0.000
n = 96Health and Quality of Life Outcomes 2007, 5:37 http://www.hqlo.com/content/5/1/37
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are the reduced sample size of the study populations; the
fact that most designs do not include a control group
(given the importance of distinguishing the impact of
HRQoL in AF patients from that of patients with other car-
diac diseases); and the bias produced, in many cases, by
questionnaires that are not self-administered by the
patients [3].
Assessment of HRQoL in these patients through a specific
questionnaire will allow to study whether differences in
patient gender and age exist, as has been observed in pre-
vious studies [20]. The relationship between clinical vari-
ables and HRQoL will also be assessed more accurately,
since the poor relationship between these two variables
has been found to be potentially grounded in that
patients' perceptions do not depend on objective meas-
urements of AF, by some authors [21]. A clear example is
the poor correlation between left ventricular dysfunction
and NYHA functional class [22]. The use of a specific
questionnaire for AF will be suitable tool for detecting
aspects in patients' lives that most affect their HRQoL and
for elaborating strategies to minimize their impact.
Current results seem to point out that the psychological
impact may be greater in patients with paroxysmal AF
than in patients with permanent AF, though the question-
naire's global scores are similar in both groups. Scores
obtained indicate a negative impact in HRQoL regardless
of the type of AF. The results of the second stage of this
project will confirm or provide more insight on the nega-
t i v e  i m p a c t  o f  A F  i n  p a t i e n t s '  H R Q o L ,  a s  h a s  b e e n
observed in different studies referenced in this article and
the results obtained in the preliminary validation of the
AF-QoL-18 Study. In the first stage of the project, the
results have been found to be coherent with those of other
studies. In such studies, women seem to have a worse
HRQoL, but the AF-Qol-18 has shown signs that the
impact on women is greater in the physical domain than
in the psychological domain. However, this aspect, as has
already been commented on, will be better established in
the second stage of this project, when a larger number of
patients will be assessed.
Conclusion
To conclude, the preliminary results of the AF-QoL-18
questionnaire seem to indicate that it can be applied in
daily clinical practice and in the clinical research context.
An assessment of the remainder of the properties, such as
test-retest reliability, longitudinal validity and the sensi-
tivity to the change of the AF-QoL-18 questionnaire, is
required to establish and assess the impact that the disease
and its treatment have on HRQoL.
It is not to be disregarded that once the validation stage is
completed, the AF-QoL-18 feasibility will improve, since
the Rasch analysis will be repeated to verify or change any
of the 18 items that were initially proposed.
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